
Employer coverage of GLP-1 drugs for weight loss fell from 57% to 53%, the first decline in three years.
Among employers maintaining coverage, 30% are considering eliminating it, according to WTW.
Employees could also face higher premiums and out-of-pocket costs as companies confront rising health expenses.
GLP-1 drugs, such as Ozempic and Wegovy, have proven to be effective weight-loss tools, leading to their increased popularity. But consumers who depend on their employers to make the drugs more affordable may be in for disappointment. Employers are pulling back from covering GLP-1 drugs for weight loss, according to a new WTW survey that points to growing pressure on workplace health benefits.
Among companies that have dropped coverage or are considering doing so, 91% cited cost. The findings specifically concern weight-loss coverage, rather than a broad withdrawal of coverage for diabetes treatment.
Author: Mark Huffman
Source: Consumer Affairs
Posted: 2026-11-09 13:25:18













